Advertisement
New Zealand markets closed
  • NZX 50

    11,946.43
    +143.15 (+1.21%)
     
  • NZD/USD

    0.5941
    +0.0004 (+0.07%)
     
  • NZD/EUR

    0.5547
    +0.0001 (+0.02%)
     
  • ALL ORDS

    7,937.50
    -0.40 (-0.01%)
     
  • ASX 200

    7,683.00
    -0.50 (-0.01%)
     
  • OIL

    82.87
    +0.06 (+0.07%)
     
  • GOLD

    2,325.00
    -13.40 (-0.57%)
     
  • NASDAQ

    17,526.80
    +55.33 (+0.32%)
     
  • FTSE

    8,040.38
    -4.43 (-0.06%)
     
  • Dow Jones

    38,460.92
    -42.77 (-0.11%)
     
  • DAX

    18,088.70
    -48.95 (-0.27%)
     
  • Hang Seng

    17,286.31
    +85.04 (+0.49%)
     
  • NIKKEI 225

    37,702.49
    -757.59 (-1.97%)
     
  • NZD/JPY

    92.3250
    +0.2100 (+0.23%)
     

Teva Pharmaceutical Focusing on Per Product Operating Profits

Teva Pharmaceutical Focusing on Per Product Operating Profits

Can Teva Pharmaceutical's Restructuring Plan Help It Recuperate? Teva Pharmaceutical Industries (TEVA) has been focused on maximizing its revenues through its market-leading generics portfolio. The company, however, has been facing stiff competition in the generics market from Mylan (MYL), Gilead Sciences (GILD), and Pfizer (PFE), which has resulted in price erosion in the generics market.